Respiratory syncytial virus (RSV) infection is the most common cause of hospital admission for children, and in the elderly population RSV is the second most common cause of death from respiratory infection after influenza virus. Most studies of RSV infection on the cellular level have been performed in cultured, immortalized cells. In these cells, RSV binds to heparan sulfate (HS), a complex oligosaccharide on the cell surface, as its primary receptor to initiate infection. In primary, well differentiated human airway epithelial (HAE) cultures, an excellent model for the airway cells that RSV targets, RSV infects only ciliated cells and only via the apical surface. But this surface has no detectable HS. RSV must, therefore, use a different receptor to enter these cells. The goals of this project are to identify that receptor and the site on the RSV attachment protein that binds to it. Both will provide novel targets for the development of novel antiviral agents against RSV.
Respiratory syncytial virus (RSV) is the most important respiratory pathogen for infants, and behind only influenza virus for the elderly. Much of what we know about the replication of RSV comes from studying the virus in immortalized cells. But it now appears that the first step in RSV infection, attachment to the target cell, is completely different in airway cells. This project will explore RSV infection of primary cells that closely model the airway epithelium, from both the virus and cell perspective.
|Grieves, Jessica L; Yin, Zhiwei; Garcia-Sastre, Adolfo et al. (2018) A viral-vectored RSV vaccine induces long-lived humoral immunity in cotton rats. Vaccine 36:3842-3852|
|Hicks, Stephanie N; Chaiwatpongsakorn, Supranee; Costello, Heather M et al. (2018) Five Residues in the Apical Loop of the Respiratory Syncytial Virus Fusion Protein F2 Subunit Are Critical for Its Fusion Activity. J Virol 92:|
|Mejias, Asuncion; Garcia-Maurino, Cristina; Rodriguez-Fernandez, Rosa et al. (2017) Development and clinical applications of novel antibodies for prevention and treatment of respiratory syncytial virus infection. Vaccine 35:496-502|
|Capella, Cristina; Chaiwatpongsakorn, Supranee; Gorrell, Erin et al. (2017) Prefusion F, Postfusion F, G Antibodies, and Disease Severity in Infants and Young Children With Acute Respiratory Syncytial Virus Infection. J Infect Dis 216:1398-1406|
|Corry, Jacqueline; Johnson, Sara M; Cornwell, Jessica et al. (2016) Preventing Cleavage of the Respiratory Syncytial Virus Attachment Protein in Vero Cells Rescues the Infectivity of Progeny Virus for Primary Human Airway Cultures. J Virol 90:1311-20|
|Johnson, Sara M; McNally, Beth A; Ioannidis, Ioannis et al. (2015) Respiratory Syncytial Virus Uses CX3CR1 as a Receptor on Primary Human Airway Epithelial Cultures. PLoS Pathog 11:e1005318|
|Ngwuta, Joan O; Chen, Man; Modjarrad, Kayvon et al. (2015) Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera. Sci Transl Med 7:309ra162|
|McGillivary, Glen; Jordan, Zachary B; Peeples, Mark E et al. (2013) Replication of respiratory syncytial virus is inhibited by the host defense molecule viperin. J Innate Immun 5:60-71|
|McLellan, Jason S; Ray, William C; Peeples, Mark E (2013) Structure and function of respiratory syncytial virus surface glycoproteins. Curr Top Microbiol Immunol 372:83-104|
|Costello, Heather M; Ray, William C; Chaiwatpongsakorn, Supranee et al. (2012) Targeting RSV with vaccines and small molecule drugs. Infect Disord Drug Targets 12:110-28|
Showing the most recent 10 out of 12 publications